News - Patents


Current filters:


Popular Filters

74 to 98 of 432 results

Avanir Pharma patent settlement with Wockhardt


USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with the US unit…

Avanir PharmaceuticalsGenericsLegalNeurologicalNorth AmericaNuedextaPatentsPharmaceuticalWockhardt

Avanir Pharma settles Nuedexta patent litigation with Actavis


USA-based Avanir Pharmaceuticals (Nasdaq: AVNR) says that it has entered into a settlement agreement…

ActavisAvanir PharmaceuticalsGenericsLegalNeurologicalNorth AmericaNuedextaPatentsPharmaceutical

Pharmaceutical patent sale of first-in-class compounds to treat women's health needs


IP Shakti, an early-stage seed fund for biomedical and life science innovations and the exclusive broker…

BezielleIP ShaktiLicensingMenerbaPatentsPharmaceuticalSealaWomen's Health

Imprimis acquires IP rights to ophthalmic compound


USA-based Imprimis Pharmaceuticals (Nasdaq: IMMY), which is focused on the commercialization of drug…

Imprimis PharmaceuticalsIPI-140OphthalmicsPatentsPharmaceutical

Actavis challenges Rayos patent


US generic drugmaker Actavis (NYSE: ACT) has confirmed filing an Abbreviated New Drug Application with…

ActavisGenericsHorizon PharmaImmunologicalsInflammatory diseasesPatentsRayos

Aid group urges countries not to trade away health as TPP negotiations intensify


The far-reaching Trans-Pacific Partnership Agreement (TPP) should be a force for improving health outcomes…


Study highlights the steps to shape effective counter-generics strategies


More than half of pharmaceutical companies - and 71% of the largest (top 10) companies - maintain a dedicated…

GenericsManagementMarkets & MarketingPatents

Horizon Pharma in Duexis patent settlement


Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

Two more drug patents revoked in India


In another blow for intellectual property in India, local drugmaker Ajanta Pharma has prevailed in revoking…

Ajanta PharmaAllerganAsia-PacificCombiganGanfortGenericsOphthalmicsPatentsPharmaceutical

Another blow for Pharma, as India revokes Tykerb patent


UK pharma giant GlaxoSmithKline (LSE: GSK) has confirmed that India's Intellectual Property Appellate…


Analyst's view on Irish pharma export woes


Following the news that Ireland's pharmaceutical industry has experienced a sharp fall in exports due…

EuropeMarkets & MarketingPatentsPharmaceuticalProduction

Mylan enters Tarceva settlement agreement


US generics firm Mylan (Nasdaq: MYL) has entered into a settlement agreement with OSI Pharmaceuticals,…

GenentechGenericsLegalMylan LaboratoriesNorth AmericaOncologyOSI PharmaceuticalsPatentsPfizerTarceva

Patent settlement curbs could reduce incentives to bring generics to market; report


A new white paper released this week, titled The Benefits of Patent Settlements: New Survey Evidence…

GenericsNorth AmericaPatentsPharmaceutical

US appeals court reverses paroxetine order in favor of Mylan


US generic drugmaker Mylan (Nasdaq: MYL) today (July 23) announced that the US Third Circuit Court of…

ApotexGenericsGlaxoSmithKlineLegalMylan LaboratoriesNeurologicalNorth AmericaparoxetinePatentsPaxil

Mylan victorious in patent dispute with Teva


US generic drugmaker Mylan (Nasdaq: MYL) says that Israel-based Teva Pharmaceuticals Industries (NYSE:…

GenericsMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalTeva Pharmaceutical Industries

Indian citizens lack free access to essential generic medicines, while policies risk undermining new drug research funding


Modern India has the third largest national economy in the world in purchasing power adjusted terms.…


US Court denies re-hearing of Arzerra patent case


Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Enhanced IP protection for medicines will help Canada with trade agreements, says think-tank


Canada's protection of intellectual property (IP) in the pharmaceutical industry falls short of international…

Markets & MarketingNorth AmericaPatentsPharmaceutical

Medecins Sans Frontieres wants the Trans-Pacific Partnership to amend terms


Worldwide humanitarian organization Medecins Sans Frontieres (MSF) is urging the countries participating…


Actavis confirms Vimpat patent challenge and gets OK for generic Opana


US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

Generics briefs: Actavis/Warner Chilcott M&A delay; Canasa patent challenge


US generics major Actavis (NYSE: ACT) and Ireland-based Warner Chilcott (Nasdaq: WCRX) have each received…

ActavisAptalis PharmaCanasaGenericsLegalMergers & AcquisitionsMylan LaboratoriesNorth AmericaPatentsWarner Chilcott

74 to 98 of 432 results

Back to top